Title : Treatment of diabetic vasculopathy with rosiglitazone and ramipril: Hype or hope?

Pub. Date : 2009 Jul

PMID : 20165647






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 This review focuses on the potential roles of rosiglitazone, a member of TZD class of antidiabetic agents, and ramipril, an ACE inhibitor, in preventing the preclinical macrovasculopathy in diabetes and IGT population. Ramipril angiotensin I converting enzyme Homo sapiens